BMY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

BM

Mkt Cap

$120.13B

Volume

7.50M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASADollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year.Zacks Investment Research · Oct 6, 2026

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?Bristol Myers Squibb (BMY) is identified as a compelling value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company's valuation metrics, including a P/S ratio of 2.54 (below industry average of 6.12) and P/CF ratio of 7.95 (below industry average of 11.40), suggest the stock is undervalued relative to its earnings outlook.Zacks Investment Research · Oct 5, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAgios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.Zacks Investment Research · Oct 2, 2026

Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global InsightsFollowing trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.GlobeNewswire Inc. · Oct 1, 2026

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowBristol Myers Squibb (BMY) is receiving significant investor attention. The stock has declined 6.1% over the past month, underperforming the S&P 500. However, the company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions and strong recent performance, with the stock trading at a valuation discount to peers. BMY beat consensus estimates in the last four quarters with an EPS surprise of +28.3% and revenue surprise of +11.15%.Zacks Investment Research · Sep 30, 2026

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth OpportunitiesThe bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.GlobeNewswire Inc. · Sep 30, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Novo Nordisk Gives Uninspiring OutlookNovo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth. The company faces challenges including the patent cliff for its blockbuster drug Ozempic, which management acknowledged as a significant concern.The Motley Fool · Sep 30, 2026

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.The Motley Fool · Sep 29, 2026

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend StocksWith traditional retirement income sources like Treasury bonds and Social Security becoming less reliable, the article recommends dividend-paying stocks from high-quality companies as an alternative income strategy for retirees. Three specific stocks are highlighted: Bristol Myers Squibb (3.94% yield), Horace Mann (3.20% yield), and H&R Block (4.56% yield), all offering steady dividend growth that can help combat inflation while reducing portfolio volatility.Zacks Investment Research · Sep 29, 2026

BM

BMYBristol-Myers Squibb Co.

BMY

Pay with—

Available Balance0.00

Your PositionYou don't own any BMY yet.

Related Tickers

Earnings

Dividends

Last · Oct 2Quarterly

Amount$0.63

Yield4.23%

Annual$2.52